Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma

PURPOSE: Prexasertib, a checkpoint kinase 1 inhibitor, demonstrated single-agent activity in patients with advanced squamous cell carcinoma (SCC) in the dose-escalation portion of a Phase I study (NCT01115790). Monotherapy prexasertib was further evaluated in patients with advanced SCC. EXPERIMENTAL...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Hong, David S., Moore, Kathleen, Patel, Manish, Grant, Stefan C., Burris, Howard A., William, William N., Jones, Suzanne, Meric-Bernstam, Funda, Infante, Jeffrey, Golden, Lisa, Zhang, Wei, Martinez, Ricardo, Wijayawardana, Sameera, Beckmann, Richard, Lin, Aimee Bence, Eng, Cathy, Bendell, Johanna
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6050086/
https://ncbi.nlm.nih.gov/pubmed/29643063
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-3347
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars